DOCSLIB.ORG

Fallopian Tube Cancers – 25-Fold Greater Than Expected Pathologypathology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Fallopian Tube Cancers – 25-Fold Greater Than Expected Pathologypathology FallopianFallopian TTuubebe CancerCancer FredFred UelanUelandd,, MMDD UniversiUniversityty ofof KentucKentuckkyy GynGynecolecoloogicgic OncolOncolooggyy AnatoAnatommyy Three layers of the fallopian tube: • Internal mucosa (endosalpinx) • Intermediate muscular layer (myosalpinx) • Outer serosa, peritoneum of the broad ligament and uterus (mesosalpinx) Tubal mucosa: 1. The endosalpinx has primary folds, increasing in number toward the fimbria 2. Lined by columnar epithelium of three types: o Ciliated o Secretory o Peg cells. BenignBenign TuTubbalal NeoplasmsNeoplasms Adenomatoid tumors Lipoma Leiomyoma Hemangioma Teratomas Lymphangioma Fibroma Mesothelioma Fibroadenoma Mesonephroma Papilloma PrePre--invasivinvasivee DiseaseDisease Carcinoma in situ (CIS) Papillary endosalpingeal lining with cytologically malignant, mitotically actice nuclei Intact basement membrane Often incidental finding at segmental salpingectomy BSO recommended – Fertility is not an issue if recent sterilization PrimaryPrimary TuTubbalal MalignanciesMalignancies AdenocarcinAdenocarcinomomaa SarcSarcomomaa ChoriocarcinChoriocarcinomomaa OtherOther – Metastases to tubes are common FallopianFallopian TTuubebe CancerCancer One of the rarest malignancies of the female genital tract – 0.3% of all gyn malignancies – 3.6 per million women Mean age at diagnosis in the 50’s – ⅔ are menopausal Risk factors – Nulliparity – Chronic salpingitis – Infertility 70% of cases FallopianFallopian TTuubebe CancerCancer PresentationPresentation Delay of diagnosis common – Only 6% were actually asymptomatic – 23% with (+) cervical cytology, including psammoma bodies Triad 1. Vaginal bleeding Present in more than 50% Postmenopausal bleeding, (-) D&C 2. Hydrops tubae profluens Colicky pain Profuse serosanguinous vaginal discharge 3. Adnexal mass AgeAge DistributionDistribution 30 25 20 15 No Patients 10 5 0 <40 40-49 50-59 60-69 70-79 >80 FIGO Report, J Epidemiol Biostat 3:99, 1998 DiagnosisDiagnosis Preoperative diagnosis is rare – 80% have known pelvic or abdominal mass noted before surgery – 10-25% have cancer on cervical cytology Sonography Serum CA-125 – London Trial, 20% of cancers detected were fallopian tube cancers – 25-fold greater than expected PathologyPathology Almost exclusively adenocarcinoma – Endometrioid – Papillary serous – Clear cell 10-25% bilaterality Peritoneal disease common before ovarian spread 87% stain for CA-125 Propensity for lymphatic spread PathologyPathology 1. MainMain ttumumoorr shoulshouldd bebe visualizedvisualized inin ttuubebe 2. TubalTubal mmucosaucosa shouldshould bebe involvedinvolved wwiithth aa papillarypapillary patpattternern wwithith histologichistologic characcharactteristieristiccss ofof thethe endosalpinx.endosalpinx. 3. IfIf thethe tubaltubal wallwall iiss involved,involved, transititransitioonn frfroomm benignbenign toto mmaalignantlignant tubaltubal epitepithhelieliumum shouldshould bebe ddeemonsmonsttratedrated Hu, AJOG 1950 CACA--125125 StaStaiiningning FallopianFallopian TTuubebe EpitheliumEpithelium LowLow MaligMalignnantant PotentialPotential SerousSerous CaCanncercer FallopianFallopian TTuubebe CancerCancer GeneticsGenetics SSimimilailarr toto ovarianovarian andand endendoomemettrialrial ccaancersncers OncogenesOncogenes – K ras, c-crb, erb b2 TTuummoorr SuppressorSuppressor GenesGenes – p53 StagingStaging FIGOFIGO establishedestablished ttubalubal carcincarcinomaoma stagingstaging systsysteemm inin 19919911 StageStage II ConfiConfinneded toto FaFallloplopiianan TubesTubes StageStage IAIA:: ConfinConfineedd toto oneone tubetube StageStage IB:IB: BothBoth tubestubes StageStage IC:IC: OneOne oror bbothoth tubestubes and:and: – Involvement of tubal serosa – Malignant ascites – (+) washings from the abdomen/pelvis StageStage IIII ConfiConfinneded toto PPeelvislvis StageStage IIIIA:A: InvolveInvolvemementnt ofof uterusuterus oror oovaries,varies, oror both.both. StageStage IIBIIB:: OtheOtherr pelvicpelvic tissuetissue – bladder, sigmoid colon, or the rectum. StageStage IICIIC:: IIIIAA oror IIIBIB withwith ((++)) wwashings,ashings, mamalignantlignant aasscitescites StageStage IIIIII ExtraExtrappelvicelvic DDiisseaseease StageStage IIIIIA:IA: MiMiccroscopicroscopic diseasdiseasee ofof uuppperper abdabdoomenmen StageStage IIIIIB:IB: UppeUpperr abdabdoominalminal involveinvolvemement,nt, butbut lessless thanthan 22 ccmm inin sizesize StageStage IIIIIC:IC: – Lymph node involvement, inguinal included. – Upper abdominal disease ≥ 2 cm StageStage IVIV DistantDistant SpreSpreadad StageStage IVIV:: DistantDistant memetastasttasisasis – Liver parenchyma – Lung parenchyma – Malignant pleural fluid – Other distant organs located outside of the peritoneal cavity SurgerySurgery anandd TreatmentTreatment FallopianFallopian TubeTube CCaancerncer RoleRole SurgeSurgerryy SSimimilailarr toto ovarianovarian cancercancer ProperProper stagingstaging forfor earearllyy disediseaasese – Adjuvant therapy CytoreductionCytoreduction ofof advancedadvanced diseasedisease – Optimal ≤ 1cm ReasseReassessmssmenentt laplapaarotrotomomyy SecondarySecondary debulkingdebulking GGOOGG SurgicalSurgical ProceduresProcedures ManualManual AdequateAdequate abdabdomominalinal incisionincision EstEstimimaattee volvolumumee ooff peritonealperitoneal fluid.fluid. IfIf nono fluid,fluid, obtainobtain washwashiingsngs frfroomm pelvispelvis aanndd abdabdoomenmen ifif suspesuspecctedted stagestage II oror IIII InspectInspect allall ppeeritonealritoneal surfacessurfaces InfraInfra--coliccolic omomenentetectctomomyy – At minimum, a biopsy must be obtained GGOOGG SurgicalSurgical ProceduresProcedures ManualManual If possible, extrafascial TAH with BSO. Unilateral SO if patient desires fertility and cancer appears stage I Resect all remaining gross disease in abdomen pelvis Selective pelvic and para-aortic lymph node sampling – Not required if stage IIIc or IV, except for cytoreduction If no gross disease, perform peritoneal biopsies – Cul-de-sac – Vesical peritoneum – Right and left pelvic sidewalls – Right and left paracolic gutters – Right hemidiaphragm TreatmentTreatment SurgicalSurgical stagingstaging aass forfor ovarianovarian canccancerer DataData lliimmitedited onon feferrtilitytility--sparingsparing surgsurgeeryry – Potential for bilaterality FourFour studiesstudies showshow nono benefitbenefit toto adjuadjuvvantant therapytherapy inin earearllyy sstatagege diseasedisease – Under staging? – 50-60% survival for stage I/II PlatinPlatinumum--basedbased ccomombinationbination chcheemmoottherapyherapy 55--YearYear SuSurrvivalvival I II III IV Overall Podratz 64 60 81 25 41 Pfeiffer 64 40 6 37 Peters 61 29 17 Muntz 100 63 - Frigerio 48 48 25 41 FIGO 84 52 36 OverallOverall SuSurvrvivalival 1 year 2 year 3 year 4 year 5 year 87.8% 69% 60% 56% 56% FIGO Report, J Epidemiol Biostat 3:99, 1998 N=83 ConclusionConclusionss 1. Very rare gynecologic malignancy 2. Serous histology most common 3. Lymphatic and peritoneal spread 4. Staging and treatment similar to ovarian cancer 5. Optimal cytoreduction 6. Survival is similar to ovarian cancer ReviewReview QuQueestionsstions Review Questions GenGeneess andand CCananccerer 1. NNameame thethe ththrreeee mamainin typestypes ofof cancanccerer protectionprotection genes.genes. 2. GiveGive anan eexamxamplplee ofof eacheach typtypee.. Review Questions GenGeneess andand CCananccerer 1. Name the three main types of cancer protection genes. 2. Give an example of each type. Tumor suppressor genes . RB (13q), p53 (17p), APC (5q21), BRCA1 (17q), BRCA2 (13q) . Oncogenes . Heregulin receptor (her-2/neu, erb-b), k-ras, h-ras, abl and src, EGF, PDGF, c-myc, cyclins . mismatch repair genes . MSH2, MLH1, MSH6, PMS1, PMS2 Review Questions PrePre--invinvaasivesive DiDisseeaasese ofof thethe VaginaVagina aanndd VulvaVulva 1. WhatWhat iiss thethe nnaameme ofof thisthis conditconditiioon?n? 2. WhatWhat araree thethe rrelatelateedd clinicalclinical conconccernernss?? Review Questions PrePre--invinvaasivesive DiDisseeaasese ofof thethe VaginaVagina aanndd VulvaVulva 1. WhatWhat iiss thethe nnaameme ofof thisthis conditconditiioon?n? . Paget’s disease of the vulva 2. WhatWhat araree thethe rrelatelateedd clinicalclinical conconccernernss?? . Synchronous or metachronous adenocarcinomas of the breast and GI tract Review Questions EndometrialEndometrial HyperHyperpplaslasiiaa aandnd HormHormoonene TTheherapyrapy 1. Based on the WHI, estrogen-alone replacement therapy increases the risk of the following: (True or False) . Breast cancer . Endometrial hyperplasia and cancer . Stroke . Improved cognition . Fracture . Thrombosis . Death Review Questions EndometrialEndometrial HyperHyperpplaslasiiaa aandnd HormHormoonene TTheherapyrapy 1. Based on the WHI, estrogen replacement therapy alone increases the risk of the following (True of False) : . Breast cancer No . Endometrial hyperplasia Yes (implied) . Stroke Yes . Improved cognition Yes . Fracture No . Thrombosis Yes . Death No! Review Questions AdenAdenoocacarrcicinonomama ofof thethe UterusUterus 1. WhatWhat araree thethe toptop threethree causecausess ofof posposttmenopausalmenopausal bblleedineedingg?? 2. ForFor typetype 22 endendomeometrialtrial ccanceancerr,, discudiscusss:s: . Typical body habitus . Common cell types and clinical course . Precursor lesion Review Questions AdenAdenoocacarrcicinonomama ofof thethe UterusUterus 1. What are the top three causes of postmenopausal bleeding? . ERT, atrophy, CA (Mayo → polyps then CA 2. For type 2 endometrial
Load more

Recommended publications
  • About Ovarian Cancer Overview and Types
    cancer.org | 1.800.227.2345 About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Ovarian Cancer? Research and Statistics See the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done. ● Key Statistics for Ovarian Cancer ● What's New in Ovarian Cancer Research? What Is Ovarian Cancer? Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer and can spread. To learn more about how cancers start and spread, see What Is Cancer?1 Ovarian cancers were previously believed to begin only in the ovaries, but recent evidence suggests that many ovarian cancers may actually start in the cells in the far (distal) end of the fallopian tubes. 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 What are the ovaries? Ovaries are reproductive glands found only in females (women). The ovaries produce eggs (ova) for reproduction. The eggs travel from the ovaries through the fallopian tubes into the uterus where the fertilized egg settles in and develops into a fetus. The ovaries are also the main source of the female hormones estrogen and progesterone. One ovary is on each side of the uterus. The ovaries are mainly made up of 3 kinds of cells. Each type of cell can develop into a different type of tumor: ● Epithelial tumors start from the cells that cover the outer surface of the ovary.
    [Show full text]
  • Primary Peritoneal Serous Papillary Carcinoma: a Case Series
    Archives of Gynecology and Obstetrics (2019) 300:1023–1028 https://doi.org/10.1007/s00404-019-05280-z GYNECOLOGIC ONCOLOGY Primary peritoneal serous papillary carcinoma: a case series Nikolaos Blontzos1 · Evangelos Vafas1 · George Vorgias1 · Nikolaos Kalinoglou1 · Christos Iavazzo1 Received: 27 May 2018 / Accepted: 22 August 2019 / Published online: 5 September 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Purpose To present the clinical and laboratory characteristics, as well as the management, of patients with primary peritoneal serous papillary carcinoma (PPSPC). Methods This is a retrospective study of 19 patients with PPSPC who underwent debulking surgery followed by frst line chemotherapy and were managed in Metaxa Memorial Cancer Hospital between January 2002 and December 2017. Results The median age of the patients was found to be 66 years (range 44–76 years). Clinical presentation of PPSPC included abdominal distention and pain, constipation, as well as loss of appetite and weight gain. Two of the patients did not mention any symptomatology and the disease was suspected by an abnormal cervical smear and elevated CA125 levels respectively. Biomarkers measurement during the initial management of the patients revealed abnormal values of CA125 for all the participants (median value 565 U/ml). Human epididymis secretory protein 4 (HE4) and ratios of blood count were also measured. Perioperative Peritoneal Cancer Index ranged from 6 to 20. Optimal debulking was achieved in 5 cases. All patients were staged as IIIC and IVA PPSPC and received standard chemotherapy with paclitaxel and carboplatin, whereas bevacizumab was added in the 5 most recent cases. Median overall survival was 29 months.
    [Show full text]
  • Capecitabine)
    Reference number(s) 1993-A SPECIALTY GUIDELINE MANAGEMENT XELODA (capecitabine) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. A. FDA-Approved Indications 1. Colorectal Cancer a. Xeloda is indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. b. Xeloda is indicated as first-line treatment in patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. 2. Breast Cancer a. Xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. b. Xeloda monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, for example, patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents. B. Compendial Uses 1. Anal cancer 2. Breast cancer 3. Central nervous system (CNS) metastases from breast cancer 4. Colorectal Cancer 5. Esophageal and esophagogastric junction cancer 6. Gastric cancer 7. Head and neck cancer 8. Hepatobiliary cancers (extra-/intra-hepatic cholangiocarcinoma and gallbladder cancer) 9. Occult primary tumors (cancer of unknown primary) 10. Ovarian cancer (Epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer/mucinous cancer) 11.
    [Show full text]
  • Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations
    International Journal of Molecular Sciences Review Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations Isao Otsuka Kameda Medical Center, Department of Obstetrics and Gynecology, Kamogawa 296-8602, Japan; [email protected] Abstract: Ovarian high-grade serous carcinomas (HGSCs) are a heterogeneous group of diseases. They include fallopian-tube-epithelium (FTE)-derived and ovarian-surface-epithelium (OSE)-derived tumors. The risk/protective factors suggest that the etiology of HGSCs is multifactorial. Inflammation caused by ovulation and retrograde bleeding may play a major role. HGSCs are among the most genetically altered cancers, and TP53 mutations are ubiquitous. Key driving events other than TP53 mutations include homologous recombination (HR) deficiency, such as BRCA 1/2 dysfunction, and activation of the CCNE1 pathway. HR deficiency and the CCNE1 amplification appear to be mutually exclusive. Intratumor heterogeneity resulting from genomic instability can be observed at the early stage of tumorigenesis. In this review, I discuss current carcinogenic hypotheses, sites of origin, etiologic factors, and molecular alterations of HGSCs. Keywords: ovarian cancer; high-grade serous carcinoma; carcinogenesis; molecular alterations Citation: Otsuka, I. Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic 1. Introduction Factors, and Molecular Alterations. Ovarian cancer is the most lethal gynecological malignancy. Epithelial ovarian cancers Int. J. Mol. Sci. 2021, 22, 4409. (EOCs) are a heterogeneous group of diseases and can be divided into five main types, https://doi.org/10.3390/ijms based on histopathology and molecular genetics [1]: high-grade serous, low-grade serous, 22094409 endometrioid, clear cell, and mucinous tumors.
    [Show full text]
  • Female Reproductive System Chapter 28
    The Female Reproductive System Chapter 28 • Female Reproductive System Anatomy • Oogenesis and the Sexual Cycle – Ovarian Cycle – Menstrual Cycle Female Reproductive System Functions: • Produce female sex hormones and gametes • Provide nutrition for fetal development • Nourish the infant after birth The Uterus • Thick-walled, pear-shaped, muscular chamber opening into vagina. • Cervix is the rounded opening of the uterus. • Two uterine tubes (also called Fallopian tubes or oviducts) branch off the uterus and terminate near the ovaries. Uterine Tubes • Also called Fallopian Tubes or Oviducts • Open-ended, muscular tube lined with secretory cells and ciliated cells that sweep secretions and peritoneal fluid towards the uterus. • Uterine Tube Regions: – narrow isthmus near the uterus – middle portion is the ampulla – flared distally into infundibulum with fimbriae • Fertilization usually occurs in ampulla or isthmus Epithelium lining the uterine tube consists of ciliated cells, goblet cells and other secretory cells. Cilia move peritoneal fluid and uterine tube secretions towards the uterus. Cervix and Vagina normally have a stratified squamous epithelium Test developed by Dr. G.N. Papanicolaou can detect cervical cancer by identifying transformed squamous cells. normal PAP smear abnormal PAP smear Histology of the Uterus • Perimetrium is the external serosa layer • Myometrium is the middle muscular layer – 1 cm thick in nonpregnant uterus – composed of smooth muscle – produces labor contractions to expel fetus during childbirth • Endometrium – simple columnar epithelium with tubular glands – stratum functionalis is superficial layer that is shed with each menstrual cycle – stratum basalis is deeper layer that regenerates a new stratum functionalis with each menstrual cycle Ovary • Ovaries produce oocytes and female hormones.
    [Show full text]
  • Clinical Pelvic Anatomy
    SECTION ONE • Fundamentals 1 Clinical pelvic anatomy Introduction 1 Anatomical points for obstetric analgesia 3 Obstetric anatomy 1 Gynaecological anatomy 5 The pelvic organs during pregnancy 1 Anatomy of the lower urinary tract 13 the necks of the femora tends to compress the pelvis Introduction from the sides, reducing the transverse diameters of this part of the pelvis (Fig. 1.1). At an intermediate level, opposite A thorough understanding of pelvic anatomy is essential for the third segment of the sacrum, the canal retains a circular clinical practice. Not only does it facilitate an understanding cross-section. With this picture in mind, the ‘average’ of the process of labour, it also allows an appreciation of diameters of the pelvis at brim, cavity, and outlet levels can the mechanisms of sexual function and reproduction, and be readily understood (Table 1.1). establishes a background to the understanding of gynae- The distortions from a circular cross-section, however, cological pathology. Congenital abnormalities are discussed are very modest. If, in circumstances of malnutrition or in Chapter 3. metabolic bone disease, the consolidation of bone is impaired, more gross distortion of the pelvic shape is liable to occur, and labour is likely to involve mechanical difficulty. Obstetric anatomy This is termed cephalopelvic disproportion. The changing cross-sectional shape of the true pelvis at different levels The bony pelvis – transverse oval at the brim and anteroposterior oval at the outlet – usually determines a fundamental feature of The girdle of bones formed by the sacrum and the two labour, i.e. that the ovoid fetal head enters the brim with its innominate bones has several important functions (Fig.
    [Show full text]
  • Recently Discovered Interstitial Cell Population of Telocytes: Distinguishing Facts from Fiction Regarding Their Role in The
    medicina Review Recently Discovered Interstitial Cell Population of Telocytes: Distinguishing Facts from Fiction Regarding Their Role in the Pathogenesis of Diverse Diseases Called “Telocytopathies” Ivan Varga 1,*, Štefan Polák 1,Ján Kyseloviˇc 2, David Kachlík 3 , L’ubošDanišoviˇc 4 and Martin Klein 1 1 Institute of Histology and Embryology, Faculty of Medicine, Comenius University in Bratislava, 813 72 Bratislava, Slovakia; [email protected] (Š.P.); [email protected] (M.K.) 2 Fifth Department of Internal Medicine, Faculty of Medicine, Comenius University in Bratislava, 813 72 Bratislava, Slovakia; [email protected] 3 Institute of Anatomy, Second Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic; [email protected] 4 Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University in Bratislava, 813 72 Bratislava, Slovakia; [email protected] * Correspondence: [email protected]; Tel.: +421-90119-547 Received: 4 December 2018; Accepted: 11 February 2019; Published: 18 February 2019 Abstract: In recent years, the interstitial cells telocytes, formerly known as interstitial Cajal-like cells, have been described in almost all organs of the human body. Although telocytes were previously thought to be localized predominantly in the organs of the digestive system, as of 2018 they have also been described in the lymphoid tissue, skin, respiratory system, urinary system, meninges and the organs of the male and female genital tracts. Since the time of eminent German pathologist Rudolf Virchow, we have known that many pathological processes originate directly from cellular changes. Even though telocytes are not widely accepted by all scientists as an individual and morphologically and functionally distinct cell population, several articles regarding telocytes have already been published in such prestigious journals as Nature and Annals of the New York Academy of Sciences.
    [Show full text]
  • XELODA (Capecitabine)
    Reference number(s) 1993-A SPECIALTY GUIDELINE MANAGEMENT XELODA (capecitabine) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. A. FDA-Approved Indications 1. Colorectal Cancer a. Xeloda is indicated as a single agent for adjuvant treatment in patients with Dukes’ C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. b. Xeloda is indicated as first-line treatment in patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. 2. Breast Cancer a. Xeloda in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. b. Xeloda monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, for example, patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents. B. Compendial Uses 1. Anal cancer 2. Breast cancer 3. Central nervous system (CNS) metastases from breast cancer 4. Colorectal Cancer 5. Esophageal and esophagogastric junction cancer 6. Gastric cancer 7. Head and neck cancers (including very advanced head and neck cancer) 8. Hepatobiliary cancers (including extrahepatic and intra-hepatic cholangiocarcinoma and gallbladder cancer) 9. Occult primary tumors (cancer of unknown primary) 10. Ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: Epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and mucinous cancer) 11.
    [Show full text]
  • The Vagina and Related Parts
    Lesson 6.5 Anatomy and Reproduction: The Vagina and Related Parts Connecting the Lessons SEL Skills Addressed Builds on Lesson 6.4: Anatomy and Reproduction: The Penis and Self-awareness, social awareness Related Parts. Planning ahead: Students will apply information learned to Lesson 6.6: Puberty and Lesson 6.7: Abstinence. Logic Model Determinant(s) Increase communication with Lesson Goals parents and other caring adults. Identify key parts of the anatomy. Increase knowledge of how pregnancy happens. Define menstrual cycle. Explain the link between menstrual cycle and reproduction. Preparation & Materials Checklist ÎTeacher Note ¨ Review the information about the vagina and related Ideally this lesson will be a dialogue anatomy in the Teacher’s Guide pages. between you and the students as ¨Review the prompt questions in the Teacher’s Guide to you cover the information. The questions in the Teacher’s Guide ask your students during this lesson. pages can help encourage student ¨Review student handouts: participation. This lesson can help correct student misconceptions – Handout 6.5-2: The Vagina and Related Parts about the vagina and related anatomy, how the parts work, and – Handout 6.5-5: “What Am I?” Homework how pregnancy and STIs can occur. ¨Copy family letter, family activity and answer key. There’s a lot of information for ¨Have: students to retain in this lesson, and much of it is presented in a – Poster of The Vagina and Related Parts way that will appeal to auditory/ verbal learners. Referring to the – Anonymous Questions Box poster of the reproductive system – Slips of paper for anonymous questions will help visual learners.
    [Show full text]
  • Gynecologic Pathology Grossing Guidelines Specimen Type
    Gynecologic Pathology Grossing Guidelines Specimen Type: TOTAL HYSTERECTOMY and SALPINGO-OOPHRECTOMY (for TUMOR) Gross Template: Labeled with the patient’s name (***), medical record number (***), designated “***”, and received [fresh/in formalin] is a *** gram [intact/previously incised/disrupted] [total/ supracervical hysterectomy/ total hysterectomy and bilateral salpingectomy, hysterectomy and bilateral salpingo-oophrectomy]. The uterus weighs [***grams] and measures *** cm (cornu-cornu) x *** cm (fundus-lower uterine segment) x *** cm (anterior - posterior). The cervix measures *** cm in length x *** cm in diameter. The endometrial cavity measures *** cm in length, up to *** cm wide. The endometrium measures *** cm in average thickness. The myometrium ranges from *** to *** cm in thickness. The right ovary measures *** x *** x *** cm. The left ovary measures *** x *** x *** cm. The right fallopian tube measures *** cm in length [with/without] fimbriae x *** cm in diameter, with a *** cm average luminal diameter. The left fallopian tube measures *** cm in length [with/without] fimbriae x *** cm in diameter, with a *** cm average luminal diameter. The serosa is [pink, smooth, glistening, unremarkable/has adhesions]. The endometrium is tan-red and remarkable for [describe lesion- location (fundus, corpus, lower uterine segment); size (***x***cm in area); color; consistency; configuration (solid, papillary, exophytic, polypoid)]. Sectioning reveals the mass has a [describe cut surface-solid, cystic, etc.]. The mass extends [less than/ greater than] 50% into the myometrium (the mass involves *** cm of the wall where the wall measures *** cm in thickness, in the [location]). The mass [does/does not] involve the lower uterine segement and measures *** cm from the cervical mucosa. The myometrium is [tan-yellow, remarkable for trabeculations, cysts, leiyomoma- (location, size)].
    [Show full text]
  • Ovarian Cancer: the New Paradigm (And What You Need to Know Clinically)
    Ovarian Cancer: The New Paradigm (and what you need to know clinically) Dianne Miller, M.D., FRCSC University of British Columbia and the British Columbia Cancer Agency Ovarian Cancer y Germ Cell: y Stromal tumors y Dysgerminoma y Lymphoma y Endodermal sinus y Sarcoma etc. y Teratoma etc. y Epithelial Tumors y Sex cord stromal y Serous y Granulosa cell y Mucinous y FOX L2 y Endometriod y Sertoli leydig etc y Clear cell etc. Objectives y To discuss why epithelial ovarian cancer is becoming vanishingly rare! y To discuss our new insights into ovarian cancer y Epithelial Ovarian Cancer is a least five distinct diseases y High Grade Serous* y Endometriod* y Clear cell* y Mucinous y Low Grade Serous y (and possibly transitional cell) y To discuss the clinical implications of the changes in our understanding of the origin of “Ovarian Cancers” “Ovarian” Cancer in Canada y modest lifetime risk of 1/70, but: y major public health issue: y 2500 new cases/annum: 1750 deaths y potential years of life lost from cancer: y breast 94,400 = 1.0 y ovary 28,600 0.3 y uterus 11,400 y cervix 10,100 International Benchmarking y The Lancet, Volume 377, Issue 9760, Pages 127 ‐ 138, 8 January 2011 y Published Online: 22 December 2010 y Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995—2007 (the International Cancer Benchmarking Partnership): an analysis of population‐based cancer registry data “Ovarian Cancer” y Screening ineffective y Survival rates low & stable “Ovarian Cancer” Presentation y 1/3 gradual intrapelvic growth → y lower
    [Show full text]
  • Specialty Guideline Management
    Reference number(s) 2040-A SPECIALTY GUIDELINE MANAGEMENT GEMZAR (gemcitabine) gemcitabine POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. A. FDA-Approved Indications 1. Ovarian cancer In combination with carboplatin for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy 2. Breast cancer In combination with paclitaxel for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated 3. Non-small cell lung cancer In combination with cisplatin for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB), or metastatic (Stage IV) non-small cell lung cancer (NSCLC) 4. Pancreatic cancer As first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemzar or gemcitabine is indicated for patients previously treated with fluorouracil. B. Compendial Uses 1. Bladder cancer, primary carcinoma of the urethra, upper genitourinary tract tumors, transitional cell carcinoma of the urinary tract, urothelial carcinoma of the prostate, non-urothelial and urothelial cancer with variant histology 2. Bone cancer a. Ewing’s sarcoma b. Osteosarcoma 3. Breast cancer 4. Head and neck cancers (including very advanced head and neck cancer and cancer of the nasopharynx) 5. Hepatobiliary and biliary tract cancer a. Extrahepatic cholangiocarcinoma b. Intrahepatic cholangiocarcinoma c.
    [Show full text]